



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Dihydromethysticin

Item No. 27644

CAS Registry No.: 19902-91-1
Formal Name: (6S)-6-[2-(1,3-benzodioxol-5-yl)ethyl]-5,6-dihydro-4-methoxy-2H-pyran-2-one
Synonyms: DHM, 7,8-dihydro Methysticin, NSC 112159
MF: C₁₅H₁₆O₅
FW: 276.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years
Item Origin: Synthetic



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Dihydromethysticin is supplied as a solid. A stock solution may be made by dissolving the dihydromethysticin in the solvent of choice, which should be purged with an inert gas. Dihydromethysticin is soluble in methanol and chloroform.

Description

Dihydromethysticin is a kavalactone originally isolated from *P. methysticum* (kava-kava) that has diverse biological activities, including efflux transporter inhibitory, antinociceptive, and neuroprotective properties.^{1,2} Dihydromethysticin is a P-glycoprotein (P-gp) inhibitor that increases uptake of the P-gp substrate calcein AM (Item No. 14948) by 50% in P388 mouse leukemia cancer cells overexpressing P-gp when used at a concentration of 54.6 μM.³ Dihydromethysticin (275 mg/kg) has analgesic activity, increasing the latency to tail withdrawal in the tail-flick assay in mice.¹ It also decreases the infarct size in a mouse model of ischemia induced by microbipolar coagulation of the left middle cerebral artery (MCA) when administered at a dose of 10 mg/kg.²

References

1. Jamieson, D.D. and Duffield, P.H. The antinociceptive actions of kava components in mice. *Clin. Exp. Pharmacol. Physiol.* **17(7)**, 495-507 (1990).
2. Backhaus, C. and Krieglstein, J. Extract of kava (*Piper methysticum*) and its methysticin constituents protect brain tissue against ischemic damage in rodent. *Eur. J. Pharmacol.* **215(2-3)**, 265-269 (1992).
3. Weiss, J., Sauer, A., Frank, A., et al. Extracts and kavalactones of *Piper methysticum* G. Forst (kava-kava) inhibit P-glycoprotein in vitro. *Drug Metab. Dispos.* **33(11)**, 1580-1583 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 08/30/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM